Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Diagnostic Significance of Exhaled Nitric Oxide (FeNO) With a Novel Technology in the Assessment of Bronchial Asthma

NCT06852911 is registered in ClinicalTrials.gov with Novlead Inc. as lead sponsor.

NCT NCT06852911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06852911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Diagnostic Significance of Exhaled Nitric Oxide (FeNO) With a Novel Technology in the Assessment of Bronchial Asthma
Lead sponsor
Novlead Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
September 12, 2024
Completion date
September 1, 2025
Enrollment
170 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

airway disease, bronchial asthma